Apr 16, 2024
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 15, 2024
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Apr 01, 2024
Viatris Announces the Launch of RYZUMVl(TM) (Phentolamine Ophthalmic Solution) 0.75% in the United States
Mar 27, 2024
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Mar 27, 2024
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Feb 28, 2024
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Feb 28, 2024
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Feb 05, 2024
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
Feb 22, 2021
Viatris Inc. Announces 2021 Financial Guidance and Reaffirms Strategic and Financial Commitments
Feb 09, 2021
Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance
Dec 18, 2020
Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi
Dec 11, 2020
Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative
Dec 10, 2020
Viatris Inc. to Present at the J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 and Will Host its Inaugural Investor Day March 1, 2021
Dec 07, 2020
Sesame Workshop and Viatris Inc. Launch Global Resources to Help Children and Caregivers Manage Social and Emotional Needs During Upcoming Holiday Season and Beyond
Nov 23, 2020
Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR
Nov 16, 2020
Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs